Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Citigroup to hold a virtual conference » 04:55
09/10/20
09/10
04:55
09/10/20
04:55
ADAP

Adaptimmune

$7.99 /

+0.15 (+1.91%)

, AMGN

Amgen

$245.46 /

+4.35 (+1.80%)

, EIGR

Eiger BioPharmaceuticals

$10.61 /

+0.29 (+2.81%)

, APLT

Applied Therapeutics

$27.31 /

+2.69 (+10.93%)

, ARVN

Arvinas

$24.18 /

-0.58 (-2.34%)

, AVRO

Avrobio

$16.57 /

+0.35 (+2.16%)

, BBIO

BridgeBio

$33.24 /

+1.12 (+3.49%)

, BMY

Bristol-Myers

$59.08 /

+0.55 (+0.94%)

, CLLS

Cellectis

$16.66 /

+0.66 (+4.13%)

, DRNA

Dicerna

$17.84 /

+0.48 (+2.76%)

, FOLD

Amicus

$13.96 /

+0.46 (+3.41%)

, IMRA

Imara

$23.06 /

+0.93 (+4.20%)

, KRTX

Karuna Therapeutics

$74.68 /

-0.73 (-0.97%)

, MRK

Merck

$84.88 /

+1.57 (+1.88%)

, NERV

Minerva

$2.88 /

+0.12 (+4.35%)

, PRVL

Prevail Therapeutics

$11.07 /

-0.45 (-3.91%)

, RCUS

Arcus Biosciences

$21.75 /

+1.03 (+4.97%)

, RIGL

Rigel Pharmaceuticals

$2.35 /

+0.07 (+3.07%)

, TPTX

Turning Point Therapeutics

$72.25 /

+0.61 (+0.85%)

15th Annual BioPharma…

15th Annual BioPharma Virtual Conference will be held on September 9-10.

ShowHide Related Items >><<
TPTX Turning Point Therapeutics
$72.25 /

+0.61 (+0.85%)

RIGL Rigel Pharmaceuticals
$2.35 /

+0.07 (+3.07%)

RCUS Arcus Biosciences
$21.75 /

+1.03 (+4.97%)

PRVL Prevail Therapeutics
$11.07 /

-0.45 (-3.91%)

NERV Minerva
$2.88 /

+0.12 (+4.35%)

MRK Merck
$84.88 /

+1.57 (+1.88%)

KRTX Karuna Therapeutics
$74.68 /

-0.73 (-0.97%)

IMRA Imara
$23.06 /

+0.93 (+4.20%)

FOLD Amicus
$13.96 /

+0.46 (+3.41%)

EIGR Eiger BioPharmaceuticals
$10.61 /

+0.29 (+2.81%)

DRNA Dicerna
$17.84 /

+0.48 (+2.76%)

CLLS Cellectis
$16.66 /

+0.66 (+4.13%)

BMY Bristol-Myers
$59.08 /

+0.55 (+0.94%)

BBIO BridgeBio
$33.24 /

+1.12 (+3.49%)

AVRO Avrobio
$16.57 /

+0.35 (+2.16%)

ARVN Arvinas
$24.18 /

-0.58 (-2.34%)

APLT Applied Therapeutics
$27.31 /

+2.69 (+10.93%)

AMGN Amgen
$245.46 /

+4.35 (+1.80%)

ADAP Adaptimmune
$7.99 /

+0.15 (+1.91%)

ADAP Adaptimmune
$7.99 /

+0.15 (+1.91%)

08/12/20 Piper Sandler
TCR2 Therapeutics initiated with an Overweight at Piper Sandler
06/01/20 Mizuho
Adaptimmune price target raised to $9 from $3 at Mizuho
05/29/20 JonesTrading
JonesTrading upgrades Adaptimmune to Buy after data alleviates 'key concern'
05/29/20 JonesTrading
Adaptimmune upgraded to Buy from Hold at JonesTrading
AMGN Amgen
$245.46 /

+4.35 (+1.80%)

09/01/20 Jefferies
Checkmate Pharmaceuticals initiated with a Buy at Jefferies
07/29/20 Piper Sandler
Piper says AbbVie's atogepant 'may yet emerge as best in class'
07/29/20 SVB Leerink
Amgen price target raised to $261 from $253 at SVB Leerink
07/29/20 Wells Fargo
Amgen price target raised to $247 from $237 at Wells Fargo
EIGR Eiger BioPharmaceuticals
$10.61 /

+0.29 (+2.81%)

APLT Applied Therapeutics
$27.31 /

+2.69 (+10.93%)

04/22/20
Fly Intel: Top five analyst initiations
04/22/20 Goldman Sachs
Applied Therapeutics initiated with a Buy at Goldman Sachs
02/27/20 Barclays
Applied Therapeutics initiated with an Overweight at Barclays
02/27/20 Barclays
Applied Therapeutics initiated with an Overweight at Barclays
ARVN Arvinas
$24.18 /

-0.58 (-2.34%)

06/01/20 Citi
Arvinas upgraded to Buy from Neutral at Citi
05/29/20 Roth Capital
Roth Capital recommends buying Arvinas on ASCO dip
05/29/20 Piper Sandler
Arvinas should be bought on weakness after ASCO update, says Piper Sandler
05/15/20 Roth Capital
Roth Capital maintains positive outlook on Arvinas after ASCO abstract review
AVRO Avrobio
$16.57 /

+0.35 (+2.16%)

03/31/20 H.C. Wainwright
Avrobio downgraded to Neutral from Buy at H.C. Wainwright
03/17/20 Janney Montgomery Scott
Avrobio weakness a buying opportunity, says Janney Montgomery Scott
02/19/20 Nomura
Avrobio price target raised to $50 from $35 at Nomura Instinet
02/11/20 Mizuho
Avrobio price target raised to $35 from $28 at Mizuho
BBIO BridgeBio
$33.24 /

+1.12 (+3.49%)

08/17/20 H.C. Wainwright
BridgeBio portfolio company granted orphan status, says H.C. Wainwright
06/25/20 BofA
BridgeBio initiated with a Neutral at BofA
06/25/20 BofA
BridgeBio initiated with a Neutral at BofA
06/05/20 Mizuho
HFA slide 'good' for BridgeBio, Eidos' AG10, says Mizuho
BMY Bristol-Myers
$59.08 /

+0.55 (+0.94%)

08/25/20 Piper Sandler
Bristol's trial miss has 'no financial impact' on Agios, says Piper Sandler
08/06/20 Citi
Investors can refocus on Bristol-Myers story after Eliquis win, says Citi
07/28/20 Mizuho
Wait for Bristol-Myers' bb2121 submission making some 'nervous,' says Mizuho
07/28/20
Fly Intel: Top five analyst initiations
CLLS Cellectis
$16.66 /

+0.66 (+4.13%)

08/19/20
Fly Intel: Top five analyst upgrades
08/19/20 Citi
Cellectis upgraded to Buy from Neutral at Citi
08/19/20 Citi
Cellectis upgraded to Buy from Neutral at Citi
05/12/20
Fly Intel: Top five analyst initiations
DRNA Dicerna
$17.84 /

+0.48 (+2.76%)

08/07/20 H.C. Wainwright
Dicerna price target raised to $35 from $32 at H.C. Wainwright
07/01/20 Baird
Dicerna elevated to Fresh Pick at Baird
05/12/20 RBC Capital
Dicerna initiated with an Outperform at RBC Capital
05/11/20 Truist
Dicerna price target raised to $33 from $28 at SunTrust
FOLD Amicus
$13.96 /

+0.46 (+3.41%)

08/11/20 Citi
Amicus price target raised to $20 from $15 at Citi
06/16/20 BTIG
Amicus initiated with a Buy at BTIG
06/16/20 H.C. Wainwright
Amicus has positive read from Sanofi COMET data, says H.C. Wainwright
06/09/20 Citi
Amicus shares worth $10 on Galafold alone, says Citi
IMRA Imara
$23.06 /

+0.93 (+4.20%)

08/17/20
Fly Intel: Top five analyst upgrades
08/17/20 Citi
Imara upgraded to Buy from Neutral at Citi
06/30/20 Citi
Imara downgraded to Neutral from Buy at Citi
04/07/20 Citi
Imara initiated with a Buy at Citi
KRTX Karuna Therapeutics
$74.68 /

-0.73 (-0.97%)

08/27/20 Mizuho
Mizuho remains buyer of Karuna on weakness from PureTech sale
08/06/20 H.C. Wainwright
Karuna Therapeutics price target lowered to $130 from $140 at H.C. Wainwright
06/24/20 Oppenheimer
Karuna Therapeutics price target raised to $135 from $125 at Oppenheimer
06/02/20 Wedbush
Karuna Therapeutics price target raised to $126 from $117 at Wedbush
MRK Merck
$84.88 /

+1.57 (+1.88%)

08/11/20 H.C. Wainwright
Pfenex acquisition fits well with Ligand growing portfolio, says H.C. Wainwright
08/04/20 Piper Sandler
Merck deal sparks interest in GLP-1:glucagon agonists, says Piper Sandler
08/03/20
Fly Intel: Top five analyst upgrades
08/03/20 Goldman Sachs
Merck upgraded to Buy from Neutral at Goldman Sachs
NERV Minerva
$2.88 /

+0.12 (+4.35%)

07/01/20 JMP Securities
Minerva's seltorexant still 'underappreciated' upside driver, says JMP
06/08/20 H.C. Wainwright
Minerva price target lowered to $10 from $20 at H.C. Wainwright
06/05/20 JMP Securities
Minerva reinstated with an Outperform at JMP Securities
06/01/20 JMP Securities
Minerva rating placed under review at JMP Securities
PRVL Prevail Therapeutics
$11.07 /

-0.45 (-3.91%)

08/11/20 Piper Sandler
Piper remains a buyer of Prevail Therapeutics after PR001 update
07/16/20
Fly Intel: Top five analyst initiations
07/15/20 Stifel
Prevail Therapeutics initiated with a Buy at Stifel
05/14/20 Piper Sandler
Prevail's 'quiet' Q1 report 'a victory in this environment,' says Piper Sandler
RCUS Arcus Biosciences
$21.75 /

+1.03 (+4.97%)

06/10/20 Truist
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/03/20 SVB Leerink
Gilead upgraded to Outperform at SVB Leerink on remdesivir sales, Arcus deal
06/02/20 Citi
Arcus Biosciences price target raised to $41 from $15 at Citi
05/27/20 Raymond James
Raymond James keeps Market Perform on Gilead following Arcus partnership
RIGL Rigel Pharmaceuticals
$2.35 /

+0.07 (+3.07%)

07/13/20 Cantor Fitzgerald
Cantor says research supports studying Rigel's fostamatinib in treating COVID-19
07/13/20 Citi
Study points to possible role for Rigel in treating COVID injury, says Citi
02/27/20 Piper Sandler
Piper Sandler continues to like Rigel Pharmaceuticals setup
01/16/20 H.C. Wainwright
Rigel launch of Tavalisse remains encouraging, says H.C. Wainwright
TPTX Turning Point Therapeutics
$72.25 /

+0.61 (+0.85%)

08/21/20 Canaccord
Turning Point Therapeutics price target raised to $85 from $80 at Canaccord
08/19/20 Roth Capital
Turning Point Therapeutics price target raised to $77 from $75 at Roth Capital
07/13/20 Roth Capital
Roth Capital positive on Turning Point Therapeutics appointment of Partridge
07/10/20
Fly Intel: Top five analyst initiations
TPTX Turning Point Therapeutics
$72.25 /

+0.61 (+0.85%)

RIGL Rigel Pharmaceuticals
$2.35 /

+0.07 (+3.07%)

RCUS Arcus Biosciences
$21.75 /

+1.03 (+4.97%)

PRVL Prevail Therapeutics
$11.07 /

-0.45 (-3.91%)

NERV Minerva
$2.88 /

+0.12 (+4.35%)

MRK Merck
$84.88 /

+1.57 (+1.88%)

KRTX Karuna Therapeutics
$74.68 /

-0.73 (-0.97%)

IMRA Imara
$23.06 /

+0.93 (+4.20%)

FOLD Amicus
$13.96 /

+0.46 (+3.41%)

EIGR Eiger BioPharmaceuticals
$10.61 /

+0.29 (+2.81%)

DRNA Dicerna
$17.84 /

+0.48 (+2.76%)

CLLS Cellectis
$16.66 /

+0.66 (+4.13%)

BMY Bristol-Myers
$59.08 /

+0.55 (+0.94%)

BBIO BridgeBio
$33.24 /

+1.12 (+3.49%)

AVRO Avrobio
$16.57 /

+0.35 (+2.16%)

ARVN Arvinas
$24.18 /

-0.58 (-2.34%)

APLT Applied Therapeutics
$27.31 /

+2.69 (+10.93%)

AMGN Amgen
$245.46 /

+4.35 (+1.80%)

ADAP Adaptimmune
$7.99 /

+0.15 (+1.91%)

  • 02
    Jun
  • 29
    May
  • 29
    May
  • 19
    May
  • 12
    Mar
  • 13
    Feb
  • 23
    Jan
  • 22
    Jan
  • 24
    Jan
  • 21
    Nov
  • 07
    Nov
RCUS Arcus Biosciences
$21.75 /

+1.03 (+4.97%)

MRK Merck
$84.88 /

+1.57 (+1.88%)

BMY Bristol-Myers
$59.08 /

+0.55 (+0.94%)

APLT Applied Therapeutics
$27.31 /

+2.69 (+10.93%)

AMGN Amgen
$245.46 /

+4.35 (+1.80%)

RIGL Rigel Pharmaceuticals
$2.35 /

+0.07 (+3.07%)

RCUS Arcus Biosciences
$21.75 /

+1.03 (+4.97%)

PRVL Prevail Therapeutics
$11.07 /

-0.45 (-3.91%)

MRK Merck
$84.88 /

+1.57 (+1.88%)

EIGR Eiger BioPharmaceuticals
$10.61 /

+0.29 (+2.81%)

CLLS Cellectis
$16.66 /

+0.66 (+4.13%)

BMY Bristol-Myers
$59.08 /

+0.55 (+0.94%)

ARVN Arvinas
$24.18 /

-0.58 (-2.34%)

APLT Applied Therapeutics
$27.31 /

+2.69 (+10.93%)

AMGN Amgen
$245.46 /

+4.35 (+1.80%)

ADAP Adaptimmune
$7.99 /

+0.15 (+1.91%)

RIGL Rigel Pharmaceuticals
$2.35 /

+0.07 (+3.07%)

RCUS Arcus Biosciences
$21.75 /

+1.03 (+4.97%)

PRVL Prevail Therapeutics
$11.07 /

-0.45 (-3.91%)

MRK Merck
$84.88 /

+1.57 (+1.88%)

BMY Bristol-Myers
$59.08 /

+0.55 (+0.94%)

AMGN Amgen
$245.46 /

+4.35 (+1.80%)

ADAP Adaptimmune
$7.99 /

+0.15 (+1.91%)

Conference/Events
Citigroup to hold a virtual conference » 07:56
09/09/20
09/09
07:56
09/09/20
07:56
ADAP

Adaptimmune

$7.86 /

-0.06 (-0.76%)

, AMGN

Amgen

$241.11 /

-7.29 (-2.93%)

, EIGR

Eiger BioPharmaceuticals

$10.31 /

+0.33 (+3.31%)

, APLT

Applied Therapeutics

$24.52 /

+0.75 (+3.16%)

, ARVN

Arvinas

$24.76 /

+0.16 (+0.65%)

, AVRO

Avrobio

$16.22 /

-0.3 (-1.82%)

, BBIO

BridgeBio

$32.08 /

+3.06 (+10.54%)

, BMY

Bristol-Myers

$58.53 /

-1.42 (-2.37%)

, CLLS

Cellectis

$16.00 /

-0.31 (-1.90%)

, DRNA

Dicerna

$17.37 /

+0.27 (+1.58%)

, FOLD

Amicus

$13.50 /

-0.13 (-0.95%)

, IMRA

Imara

$22.02 /

-0.5 (-2.22%)

, KRTX

Karuna Therapeutics

$75.35 /

+0.88 (+1.18%)

, MRK

Merck

$83.31 /

-1.95 (-2.29%)

, NERV

Minerva

$2.76 /

-0.165 (-5.64%)

, PRVL

Prevail Therapeutics

$11.52 /

-0.4 (-3.36%)

, RCUS

Arcus Biosciences

$20.72 /

-0.28 (-1.33%)

, RIGL

Rigel Pharmaceuticals

$2.28 /

-0.015 (-0.65%)

, TPTX

Turning Point Therapeutics

$71.64 /

-0.71 (-0.98%)

15th Annual BioPharma…

15th Annual BioPharma Virtual Conference will be held on September 9-10.

ShowHide Related Items >><<
TPTX Turning Point Therapeutics
$71.64 /

-0.71 (-0.98%)

RIGL Rigel Pharmaceuticals
$2.28 /

-0.015 (-0.65%)

RCUS Arcus Biosciences
$20.72 /

-0.28 (-1.33%)

PRVL Prevail Therapeutics
$11.52 /

-0.4 (-3.36%)

NERV Minerva
$2.76 /

-0.165 (-5.64%)

MRK Merck
$83.31 /

-1.95 (-2.29%)

KRTX Karuna Therapeutics
$75.35 /

+0.88 (+1.18%)

IMRA Imara
$22.02 /

-0.5 (-2.22%)

FOLD Amicus
$13.50 /

-0.13 (-0.95%)

EIGR Eiger BioPharmaceuticals
$10.31 /

+0.33 (+3.31%)

DRNA Dicerna
$17.37 /

+0.27 (+1.58%)

CLLS Cellectis
$16.00 /

-0.31 (-1.90%)

BMY Bristol-Myers
$58.53 /

-1.42 (-2.37%)

BBIO BridgeBio
$32.08 /

+3.06 (+10.54%)

AVRO Avrobio
$16.22 /

-0.3 (-1.82%)

ARVN Arvinas
$24.76 /

+0.16 (+0.65%)

APLT Applied Therapeutics
$24.52 /

+0.75 (+3.16%)

AMGN Amgen
$241.11 /

-7.29 (-2.93%)

ADAP Adaptimmune
$7.86 /

-0.06 (-0.76%)

ADAP Adaptimmune
$7.86 /

-0.06 (-0.76%)

08/12/20 Piper Sandler
TCR2 Therapeutics initiated with an Overweight at Piper Sandler
06/01/20 Mizuho
Adaptimmune price target raised to $9 from $3 at Mizuho
05/29/20 JonesTrading
JonesTrading upgrades Adaptimmune to Buy after data alleviates 'key concern'
05/29/20 JonesTrading
Adaptimmune upgraded to Buy from Hold at JonesTrading
AMGN Amgen
$241.11 /

-7.29 (-2.93%)

09/01/20 Jefferies
Checkmate Pharmaceuticals initiated with a Buy at Jefferies
07/29/20 Piper Sandler
Piper says AbbVie's atogepant 'may yet emerge as best in class'
07/29/20 SVB Leerink
Amgen price target raised to $261 from $253 at SVB Leerink
07/29/20 Wells Fargo
Amgen price target raised to $247 from $237 at Wells Fargo
EIGR Eiger BioPharmaceuticals
$10.31 /

+0.33 (+3.31%)

APLT Applied Therapeutics
$24.52 /

+0.75 (+3.16%)

04/22/20
Fly Intel: Top five analyst initiations
04/22/20 Goldman Sachs
Applied Therapeutics initiated with a Buy at Goldman Sachs
02/27/20 Barclays
Applied Therapeutics initiated with an Overweight at Barclays
02/27/20 Barclays
Applied Therapeutics initiated with an Overweight at Barclays
ARVN Arvinas
$24.76 /

+0.16 (+0.65%)

06/01/20 Citi
Arvinas upgraded to Buy from Neutral at Citi
05/29/20 Roth Capital
Roth Capital recommends buying Arvinas on ASCO dip
05/29/20 Piper Sandler
Arvinas should be bought on weakness after ASCO update, says Piper Sandler
05/15/20 Roth Capital
Roth Capital maintains positive outlook on Arvinas after ASCO abstract review
AVRO Avrobio
$16.22 /

-0.3 (-1.82%)

03/31/20 H.C. Wainwright
Avrobio downgraded to Neutral from Buy at H.C. Wainwright
03/17/20 Janney Montgomery Scott
Avrobio weakness a buying opportunity, says Janney Montgomery Scott
02/19/20 Nomura
Avrobio price target raised to $50 from $35 at Nomura Instinet
02/11/20 Mizuho
Avrobio price target raised to $35 from $28 at Mizuho
BBIO BridgeBio
$32.08 /

+3.06 (+10.54%)

08/17/20 H.C. Wainwright
BridgeBio portfolio company granted orphan status, says H.C. Wainwright
06/25/20 BofA
BridgeBio initiated with a Neutral at BofA
06/25/20 BofA
BridgeBio initiated with a Neutral at BofA
06/05/20 Mizuho
HFA slide 'good' for BridgeBio, Eidos' AG10, says Mizuho
BMY Bristol-Myers
$58.53 /

-1.42 (-2.37%)

08/25/20 Piper Sandler
Bristol's trial miss has 'no financial impact' on Agios, says Piper Sandler
08/06/20 Citi
Investors can refocus on Bristol-Myers story after Eliquis win, says Citi
07/28/20 Mizuho
Wait for Bristol-Myers' bb2121 submission making some 'nervous,' says Mizuho
07/28/20
Fly Intel: Top five analyst initiations
CLLS Cellectis
$16.00 /

-0.31 (-1.90%)

08/19/20
Fly Intel: Top five analyst upgrades
08/19/20 Citi
Cellectis upgraded to Buy from Neutral at Citi
08/19/20 Citi
Cellectis upgraded to Buy from Neutral at Citi
05/12/20
Fly Intel: Top five analyst initiations
DRNA Dicerna
$17.37 /

+0.27 (+1.58%)

08/07/20 H.C. Wainwright
Dicerna price target raised to $35 from $32 at H.C. Wainwright
07/01/20 Baird
Dicerna elevated to Fresh Pick at Baird
05/12/20 RBC Capital
Dicerna initiated with an Outperform at RBC Capital
05/11/20 Truist
Dicerna price target raised to $33 from $28 at SunTrust
FOLD Amicus
$13.50 /

-0.13 (-0.95%)

08/11/20 Citi
Amicus price target raised to $20 from $15 at Citi
06/16/20 BTIG
Amicus initiated with a Buy at BTIG
06/16/20 H.C. Wainwright
Amicus has positive read from Sanofi COMET data, says H.C. Wainwright
06/09/20 Citi
Amicus shares worth $10 on Galafold alone, says Citi
IMRA Imara
$22.02 /

-0.5 (-2.22%)

08/17/20
Fly Intel: Top five analyst upgrades
08/17/20 Citi
Imara upgraded to Buy from Neutral at Citi
06/30/20 Citi
Imara downgraded to Neutral from Buy at Citi
04/07/20 Citi
Imara initiated with a Buy at Citi
KRTX Karuna Therapeutics
$75.35 /

+0.88 (+1.18%)

08/27/20 Mizuho
Mizuho remains buyer of Karuna on weakness from PureTech sale
08/06/20 H.C. Wainwright
Karuna Therapeutics price target lowered to $130 from $140 at H.C. Wainwright
06/24/20 Oppenheimer
Karuna Therapeutics price target raised to $135 from $125 at Oppenheimer
06/02/20 Wedbush
Karuna Therapeutics price target raised to $126 from $117 at Wedbush
MRK Merck
$83.31 /

-1.95 (-2.29%)

08/11/20 H.C. Wainwright
Pfenex acquisition fits well with Ligand growing portfolio, says H.C. Wainwright
08/04/20 Piper Sandler
Merck deal sparks interest in GLP-1:glucagon agonists, says Piper Sandler
08/03/20
Fly Intel: Top five analyst upgrades
08/03/20 Goldman Sachs
Merck upgraded to Buy from Neutral at Goldman Sachs
NERV Minerva
$2.76 /

-0.165 (-5.64%)

07/01/20 JMP Securities
Minerva's seltorexant still 'underappreciated' upside driver, says JMP
06/08/20 H.C. Wainwright
Minerva price target lowered to $10 from $20 at H.C. Wainwright
06/05/20 JMP Securities
Minerva reinstated with an Outperform at JMP Securities
06/01/20 JMP Securities
Minerva rating placed under review at JMP Securities
PRVL Prevail Therapeutics
$11.52 /

-0.4 (-3.36%)

08/11/20 Piper Sandler
Piper remains a buyer of Prevail Therapeutics after PR001 update
07/16/20
Fly Intel: Top five analyst initiations
07/15/20 Stifel
Prevail Therapeutics initiated with a Buy at Stifel
05/14/20 Piper Sandler
Prevail's 'quiet' Q1 report 'a victory in this environment,' says Piper Sandler
RCUS Arcus Biosciences
$20.72 /

-0.28 (-1.33%)

06/10/20 Truist
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/03/20 SVB Leerink
Gilead upgraded to Outperform at SVB Leerink on remdesivir sales, Arcus deal
06/02/20 Citi
Arcus Biosciences price target raised to $41 from $15 at Citi
05/27/20 Raymond James
Raymond James keeps Market Perform on Gilead following Arcus partnership
RIGL Rigel Pharmaceuticals
$2.28 /

-0.015 (-0.65%)

07/13/20 Cantor Fitzgerald
Cantor says research supports studying Rigel's fostamatinib in treating COVID-19
07/13/20 Citi
Study points to possible role for Rigel in treating COVID injury, says Citi
02/27/20 Piper Sandler
Piper Sandler continues to like Rigel Pharmaceuticals setup
01/16/20 H.C. Wainwright
Rigel launch of Tavalisse remains encouraging, says H.C. Wainwright
TPTX Turning Point Therapeutics
$71.64 /

-0.71 (-0.98%)

08/21/20 Canaccord
Turning Point Therapeutics price target raised to $85 from $80 at Canaccord
08/19/20 Roth Capital
Turning Point Therapeutics price target raised to $77 from $75 at Roth Capital
07/13/20 Roth Capital
Roth Capital positive on Turning Point Therapeutics appointment of Partridge
07/10/20
Fly Intel: Top five analyst initiations
TPTX Turning Point Therapeutics
$71.64 /

-0.71 (-0.98%)

RIGL Rigel Pharmaceuticals
$2.28 /

-0.015 (-0.65%)

RCUS Arcus Biosciences
$20.72 /

-0.28 (-1.33%)

PRVL Prevail Therapeutics
$11.52 /

-0.4 (-3.36%)

NERV Minerva
$2.76 /

-0.165 (-5.64%)

MRK Merck
$83.31 /

-1.95 (-2.29%)

KRTX Karuna Therapeutics
$75.35 /

+0.88 (+1.18%)

IMRA Imara
$22.02 /

-0.5 (-2.22%)

FOLD Amicus
$13.50 /

-0.13 (-0.95%)

EIGR Eiger BioPharmaceuticals
$10.31 /

+0.33 (+3.31%)

DRNA Dicerna
$17.37 /

+0.27 (+1.58%)

CLLS Cellectis
$16.00 /

-0.31 (-1.90%)

BMY Bristol-Myers
$58.53 /

-1.42 (-2.37%)

BBIO BridgeBio
$32.08 /

+3.06 (+10.54%)

AVRO Avrobio
$16.22 /

-0.3 (-1.82%)

ARVN Arvinas
$24.76 /

+0.16 (+0.65%)

APLT Applied Therapeutics
$24.52 /

+0.75 (+3.16%)

AMGN Amgen
$241.11 /

-7.29 (-2.93%)

ADAP Adaptimmune
$7.86 /

-0.06 (-0.76%)

  • 02
    Jun
  • 29
    May
  • 29
    May
  • 19
    May
  • 12
    Mar
  • 13
    Feb
  • 23
    Jan
  • 22
    Jan
  • 24
    Jan
  • 21
    Nov
  • 07
    Nov
RCUS Arcus Biosciences
$20.72 /

-0.28 (-1.33%)

MRK Merck
$83.31 /

-1.95 (-2.29%)

BMY Bristol-Myers
$58.53 /

-1.42 (-2.37%)

APLT Applied Therapeutics
$24.52 /

+0.75 (+3.16%)

AMGN Amgen
$241.11 /

-7.29 (-2.93%)

RIGL Rigel Pharmaceuticals
$2.28 /

-0.015 (-0.65%)

RCUS Arcus Biosciences
$20.72 /

-0.28 (-1.33%)

PRVL Prevail Therapeutics
$11.52 /

-0.4 (-3.36%)

MRK Merck
$83.31 /

-1.95 (-2.29%)

EIGR Eiger BioPharmaceuticals
$10.31 /

+0.33 (+3.31%)

CLLS Cellectis
$16.00 /

-0.31 (-1.90%)

BMY Bristol-Myers
$58.53 /

-1.42 (-2.37%)

ARVN Arvinas
$24.76 /

+0.16 (+0.65%)

APLT Applied Therapeutics
$24.52 /

+0.75 (+3.16%)

AMGN Amgen
$241.11 /

-7.29 (-2.93%)

ADAP Adaptimmune
$7.86 /

-0.06 (-0.76%)

RIGL Rigel Pharmaceuticals
$2.28 /

-0.015 (-0.65%)

RCUS Arcus Biosciences
$20.72 /

-0.28 (-1.33%)

PRVL Prevail Therapeutics
$11.52 /

-0.4 (-3.36%)

MRK Merck
$83.31 /

-1.95 (-2.29%)

BMY Bristol-Myers
$58.53 /

-1.42 (-2.37%)

AMGN Amgen
$241.11 /

-7.29 (-2.93%)

ADAP Adaptimmune
$7.86 /

-0.06 (-0.76%)

Over a month ago
Upgrade
Fly Intel: Top five analyst upgrades » 09:49
08/19/20
08/19
09:49
08/19/20
09:49
XPO

XPO Logistics

$85.27 /

+4.39 (+5.43%)

, HD

Home Depot

$286.60 /

+1.5 (+0.53%)

, CLLS

Cellectis

$19.37 /

+1.5 (+8.39%)

, PFPT

Proofpoint

$113.00 /

+4.77 (+4.41%)

, FFG

FBL Financial

$37.32 /

+1.03 (+2.84%)

Catch up on today's…

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. XPO Logistics (XPO) upgraded to Overweight from Sector Weight at KeyBanc with analyst Todd Fowler saying the company's multiple expansion has lagged peers, but an updated sum of the parts analysis suggests share upside in a cyclical recovery. 2. Home Depot (HD) upgraded to Buy from Neutral at BofA with analyst Elizabeth Suzuki citing the company's "record" Q2 results and believing that the quarter will not be the last of its "strong run." 3. Cellectis (CLLS) upgraded to Buy from Neutral at Citi with analyst Yigal Nochomovitz stating he believes Cellectis' "differentiated" off-the-shelf CART pipeline is being overlooked by investors. 4. Proofpoint (PFPT) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Hamza Fodderwala continuing to see the company as a leading share gainer in the email security market, while also gaining traction in emerging adjacent market opportunities such as cloud app security, data loss prevention and security awareness training. 5. FBL Financial (FFG) upgraded to Outperform from Market Perform at Raymond James with analyst C. Gregory Peters saying he believes FBL Financial represents a more compelling risk/reward opportunity relative to other spread-based businesses in his coverage universe. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
XPO XPO Logistics
$85.27 /

+4.39 (+5.43%)

PFPT Proofpoint
$113.00 /

+4.77 (+4.41%)

HD Home Depot
$286.60 /

+1.5 (+0.53%)

FFG FBL Financial
$37.32 /

+1.03 (+2.84%)

CLLS Cellectis
$19.37 /

+1.5 (+8.39%)

XPO XPO Logistics
$85.27 /

+4.39 (+5.43%)

08/19/20 KeyBanc
KeyBanc upgrades XPO Logistics to Overweight with $110 price target
08/18/20 KeyBanc
XPO Logistics upgraded to Overweight from Sector Weight at KeyBanc
08/03/20 Deutsche Bank
XPO results show company should be broken up, says Deutsche Bank
07/17/20 Truist
SunTrust raises price targets in select Trucking/Logistics names
HD Home Depot
$286.60 /

+1.5 (+0.53%)

08/19/20 DA Davidson
Home Depot price target raised to $315 from $290 at DA Davidson
08/19/20 Jefferies
Home Depot price target raised to $332 from $306 at Jefferies
08/19/20 Wedbush
Home Depot price target raised to $300 from $270 at Wedbush
08/19/20 Loop Capital
Home Depot price target raised to $330 from $275 at Loop Capital
CLLS Cellectis
$19.37 /

+1.5 (+8.39%)

08/19/20 Citi
Cellectis upgraded to Buy from Neutral at Citi
08/19/20 Citi
Cellectis upgraded to Buy from Neutral at Citi
05/12/20
Fly Intel: Top five analyst initiations
05/11/20 Baird
Cellectis initiated with an Outperform at Baird
PFPT Proofpoint
$113.00 /

+4.77 (+4.41%)

08/19/20 Morgan Stanley
Proofpoint upgraded to Overweight from Equal Weight at Morgan Stanley
07/31/20 Northland
Proofpoint price target raised to $153 from $145 at Northland
07/31/20 Piper Sandler
Proofpoint price target raised to $150 from $140 at Piper Sandler
07/21/20 Guggenheim
CyberArk price target raised to $128 from $115 at Guggenheim
FFG FBL Financial
$37.32 /

+1.03 (+2.84%)

08/19/20 Raymond James
FBL Financial a compelling risk/reward opportunity, says Raymond James
08/19/20 Raymond James
FBL Financial upgraded to Outperform from Market Perform at Raymond James
03/16/20 Sidoti
FBL Financial initiated with a Buy at Sidoti
11/05/19 Raymond James
FBL Financial upgraded to Market Perform after underperformance at Raymond James
XPO XPO Logistics
$85.27 /

+4.39 (+5.43%)

PFPT Proofpoint
$113.00 /

+4.77 (+4.41%)

HD Home Depot
$286.60 /

+1.5 (+0.53%)

FFG FBL Financial
$37.32 /

+1.03 (+2.84%)

CLLS Cellectis
$19.37 /

+1.5 (+8.39%)

PFPT Proofpoint
$113.00 /

+4.77 (+4.41%)

HD Home Depot
$286.60 /

+1.5 (+0.53%)

XPO XPO Logistics
$85.27 /

+4.39 (+5.43%)

PFPT Proofpoint
$113.00 /

+4.77 (+4.41%)

HD Home Depot
$286.60 /

+1.5 (+0.53%)

CLLS Cellectis
$19.37 /

+1.5 (+8.39%)

XPO XPO Logistics
$85.27 /

+4.39 (+5.43%)

HD Home Depot
$286.60 /

+1.5 (+0.53%)

Upgrade
Cellectis upgraded to Buy from Neutral at Citi » 06:30
08/19/20
08/19
06:30
08/19/20
06:30
CLLS

Cellectis

$17.87 /

+0.65 (+3.77%)

Citi analyst Yigal…

Citi analyst Yigal Nochomovitz upgraded Cellectis to Buy from Neutral with a price target of $32, up from $15. The analyst believes Cellectis' "differentiated" off-the-shelf CART pipeline is being overlooked by investors. The company's TALEN gene-edited allogeneic CART platform is the same technology originally licensed to Pfizer that underpinned Allogene's ALLO-501 data, Nochomovitz tells investors in a research note. As such, the ALLO-501 data "meaningfully de-risk" Cellectis' wholly-owned CART pipeline, says the analyst.

ShowHide Related Items >><<
CLLS Cellectis
$17.87 /

+0.65 (+3.77%)

CLLS Cellectis
$17.87 /

+0.65 (+3.77%)

08/19/20 Citi
Cellectis upgraded to Buy from Neutral at Citi
05/12/20
Fly Intel: Top five analyst initiations
05/11/20 Baird
Cellectis initiated with an Outperform at Baird
03/06/20 Citi
Cellectis price target raised to $16 from $14 at Citi
CLLS Cellectis
$17.87 /

+0.65 (+3.77%)

CLLS Cellectis
$17.87 /

+0.65 (+3.77%)

Upgrade
Cellectis upgraded to Buy from Neutral at Citi » 06:22
08/19/20
08/19
06:22
08/19/20
06:22
CLLS

Cellectis

$17.87 /

+0.65 (+3.77%)

Citi analyst Yigal…

Citi analyst Yigal Nochomovitz upgraded Cellectis to Buy from Neutral.

ShowHide Related Items >><<
CLLS Cellectis
$17.87 /

+0.65 (+3.77%)

CLLS Cellectis
$17.87 /

+0.65 (+3.77%)

05/12/20
Fly Intel: Top five analyst initiations
05/11/20 Baird
Cellectis initiated with an Outperform at Baird
03/06/20 Citi
Cellectis price target raised to $16 from $14 at Citi
03/06/20 Goldman Sachs
Cellectis downgraded to Sell from Neutral at Goldman Sachs
CLLS Cellectis
$17.87 /

+0.65 (+3.77%)

CLLS Cellectis
$17.87 /

+0.65 (+3.77%)

Hot Stocks
Bpifrance Participations reports 8.5% stake in Cellectis » 13:50
08/04/20
08/04
13:50
08/04/20
13:50
CLLS

Cellectis

$17.04 /

-0.4 (-2.29%)

Bpifrance Participations…

Bpifrance Participations disclosed an 8.5% stake in Cellectis, which represents 3.6M shares. The filing with the SEC allows for activism.

ShowHide Related Items >><<
CLLS Cellectis
$17.04 /

-0.4 (-2.29%)

CLLS Cellectis
$17.04 /

-0.4 (-2.29%)

05/12/20
Fly Intel: Top five analyst initiations
05/11/20 Baird
Cellectis initiated with an Outperform at Baird
03/06/20 Citi
Cellectis price target raised to $16 from $14 at Citi
03/06/20 Goldman Sachs
Cellectis downgraded to Sell from Neutral at Goldman Sachs
CLLS Cellectis
$17.04 /

-0.4 (-2.29%)

CLLS Cellectis
$17.04 /

-0.4 (-2.29%)

Conference/Events
William Blair to hold a virtual conference » 09:55
08/04/20
08/04
09:55
08/04/20
09:55
RCUS

Arcus Biosciences

$20.42 /

-0.61 (-2.90%)

, AGEN

Agenus

$3.20 /

-0.055 (-1.69%)

, EXEL

Exelixis

$23.06 /

-0.64 (-2.70%)

, CALA

Calithera Biosciences

$4.85 /

-0.02 (-0.41%)

, RGEN

Repligen

$155.50 /

-3.02 (-1.91%)

, PIRS

Pieris Pharmaceuticals

$2.68 /

-0.025 (-0.92%)

, CYAD

Celyad

$9.87 /

+ (+0.00%)

, FATE

Fate Therapeutics

$32.33 /

-0.92 (-2.77%)

, CLLS

Cellectis

$17.44 /

+ (+0.00%)

, AUTL

Autolus Therapeutics

$13.92 /

+ (+0.00%)

, GRTS

Gritstone Oncology

$3.35 /

+0.03 (+0.90%)

, ADPT

Adaptive Biotechnologies

$39.49 /

+0.12 (+0.30%)

, TBIO

Translate Bio

$15.60 /

-0.14 (-0.89%)

, EBS

Emergent BioSolutions

$122.01 /

+4.045 (+3.43%)

, ITCI

Intra-Cellular

$20.77 /

-0.15 (-0.72%)

, KRTX

Karuna Therapeutics

$86.82 /

-0.68 (-0.78%)

, ASMB

Assembly Biosciences

$23.15 /

+0.03 (+0.13%)

, NCNA

NuCana

$6.55 /

+0.4 (+6.50%)

, AXSM

Axsome Therapeutics

$74.50 /

-1.82 (-2.38%)

, OVID

Ovid Therapeutics

$6.61 /

-0.16 (-2.36%)

, ALLK

Allakos

$78.92 /

-0.57 (-0.72%)

, NBIX

Neurocrine

$124.09 /

+0.92 (+0.75%)

, XENE

Xenon Pharmaceuticals

$11.51 /

+ (+0.00%)

, CRSP

Crispr Therapeutics

$91.70 /

-0.85 (-0.92%)

, BEAM

Beam Therapeutics

$19.00 /

+0.03 (+0.16%)

, GBT

Global Blood Therapeutics

$68.59 /

-2.08 (-2.94%)

, IONS

Ionis Pharmaceuticals

$58.45 /

-0.78 (-1.32%)

, RTRX

Retrophin

$20.19 /

+ (+0.00%)

Biotech Focus Virtual…

Biotech Focus Virtual Conference 2020 will be held on August 4-6 beginning at 10 am on August 4. Webcast Link

ShowHide Related Items >><<
XENE Xenon Pharmaceuticals
$11.51 /

+ (+0.00%)

TBIO Translate Bio
$15.60 /

-0.14 (-0.89%)

RTRX Retrophin
$20.19 /

+ (+0.00%)

RGEN Repligen
$155.50 /

-3.02 (-1.91%)

RCUS Arcus Biosciences
$20.42 /

-0.61 (-2.90%)

PIRS Pieris Pharmaceuticals
$2.68 /

-0.025 (-0.92%)

OVID Ovid Therapeutics
$6.61 /

-0.16 (-2.36%)

NCNA NuCana
$6.55 /

+0.4 (+6.50%)

NBIX Neurocrine
$124.09 /

+0.92 (+0.75%)

KRTX Karuna Therapeutics
$86.82 /

-0.68 (-0.78%)

ITCI Intra-Cellular
$20.77 /

-0.15 (-0.72%)

IONS Ionis Pharmaceuticals
$58.45 /

-0.78 (-1.32%)

GRTS Gritstone Oncology
$3.35 /

+0.03 (+0.90%)

GBT Global Blood Therapeutics
$68.59 /

-2.08 (-2.94%)

FATE Fate Therapeutics
$32.33 /

-0.92 (-2.77%)

EXEL Exelixis
$23.06 /

-0.64 (-2.70%)

EBS Emergent BioSolutions
$122.01 /

+4.045 (+3.43%)

CYAD Celyad
$9.87 /

+ (+0.00%)

CRSP Crispr Therapeutics
$91.70 /

-0.85 (-0.92%)

CLLS Cellectis
$17.44 /

+ (+0.00%)

CALA Calithera Biosciences
$4.85 /

-0.02 (-0.41%)

BEAM Beam Therapeutics
$19.00 /

+0.03 (+0.16%)

AXSM Axsome Therapeutics
$74.50 /

-1.82 (-2.38%)

AUTL Autolus Therapeutics
$13.92 /

+ (+0.00%)

ASMB Assembly Biosciences
$23.15 /

+0.03 (+0.13%)

ALLK Allakos
$78.92 /

-0.57 (-0.72%)

AGEN Agenus
$3.20 /

-0.055 (-1.69%)

ADPT Adaptive Biotechnologies
$39.49 /

+0.12 (+0.30%)

RCUS Arcus Biosciences
$20.42 /

-0.61 (-2.90%)

06/10/20 Truist
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/03/20 SVB Leerink
Gilead upgraded to Outperform at SVB Leerink on remdesivir sales, Arcus deal
06/02/20 Citi
Arcus Biosciences price target raised to $41 from $15 at Citi
05/27/20 Raymond James
Raymond James keeps Market Perform on Gilead following Arcus partnership
AGEN Agenus
$3.20 /

-0.055 (-1.69%)

01/09/20 B. Riley Securities
Arbutus Biopharma price target raised to $6 from $3 at B. Riley FBR
11/19/19
Fly Intel: Top five analyst initiations
11/19/19 B. Riley Securities
Agenus resumed with a Buy at B. Riley FBR
11/19/19 B. Riley Securities
Agenus resumed with a Buy at B. Riley FBR
EXEL Exelixis
$23.06 /

-0.64 (-2.70%)

06/30/20 Piper Sandler
Exelixis' 2/3 Phase III Contact studies underway, says Piper Sandler
05/14/20 Truist
Exelixis price target raised to $40 from $35 at SunTrust
05/13/20 Piper Sandler
Exelixis mCRPC data for CABOMETYX may accelerate approval, says Piper Sandler
05/06/20 Piper Sandler
Exelixis price target raised to $30 from $23 at Piper Sandler
CALA Calithera Biosciences
$4.85 /

-0.02 (-0.41%)

05/11/20 Citi
Calithera Biosciences price target raised to $10 from $7 at Citi
05/08/20 H.C. Wainwright
Calithera Biosciences price target raised to $9.50 from $7 at H.C. Wainwright
03/27/20
Fly Intel: Top five analyst initiations
03/27/20 Jefferies
Jefferies starts Calithera at Buy ahead of three data catalysts
RGEN Repligen
$155.50 /

-3.02 (-1.91%)

06/30/20 H.C. Wainwright
Repligen price target raised to $151 from $143 at H.C. Wainwright
05/27/20 Stifel
Repligen price target raised to $150 from $135 at Stifel
05/07/20 Craig-Hallum
Repligen price target raised to $145 from $120 at Craig-Hallum
05/07/20 H.C. Wainwright
Repligen price target raised to $143 from $100 at H.C. Wainwright
PIRS Pieris Pharmaceuticals
$2.68 /

-0.025 (-0.92%)

03/13/20 Baird
Baird upgrades Pieris Pharmaceuticals as pipeline updates expected
03/13/20 Baird
Pieris Pharmaceuticals upgraded to Outperform from Neutral at Baird
03/12/20 H.C. Wainwright
Increased visibility in 2020 expected for Pieris, says H.C. Wainwright
01/27/20 H.C. Wainwright
Pieris Pharmaceuticals price target raised to $9 from $7 at H.C. Wainwright
CYAD Celyad
$9.87 /

+ (+0.00%)

03/26/20 Wells Fargo
Celyad price target lowered to $20 from $44 at Wells Fargo
03/25/20 H.C. Wainwright
Celyad price target lowered to $37 from $43 at H.C. Wainwright
FATE Fate Therapeutics
$32.33 /

-0.92 (-2.77%)

06/10/20 Oppenheimer
Fate Therapeutics price target raised to $40 from $34 at Oppenheimer
06/09/20 Piper Sandler
Fate Therapeutics price target lowered to $59 from $63 at Piper Sandler
05/13/20
Fly Intel: Top five analyst initiations
05/13/20 H.C. Wainwright
Fate Therapeutics initiated with a Buy at H.C. Wainwright
CLLS Cellectis
$17.44 /

+ (+0.00%)

05/12/20
Fly Intel: Top five analyst initiations
05/11/20 Baird
Cellectis initiated with an Outperform at Baird
03/06/20 Citi
Cellectis price target raised to $16 from $14 at Citi
03/06/20 Goldman Sachs
Cellectis downgraded to Sell from Neutral at Goldman Sachs
AUTL Autolus Therapeutics
$13.92 /

+ (+0.00%)

07/31/20
Fly Intel: Top five analyst initiations
07/31/20 JPMorgan
Autolus Therapeutics initiated with an Overweight at JPMorgan
07/22/20 Truist
Autolus Therapeutics initiated with a Buy at SunTrust
07/22/20 Truist
Autolus Therapeutics initiated with a Buy at SunTrust
GRTS Gritstone Oncology
$3.35 /

+0.03 (+0.90%)

07/14/20 BTIG
Gritstone Oncology price target lowered to $17 from $31 at BTIG
ADPT Adaptive Biotechnologies
$39.49 /

+0.12 (+0.30%)

06/18/20 Guggenheim
Adaptive to benefit from increased MRD testing by oncologists, says Guggenheim
06/03/20
Fly Intel: Top five analyst initiations
06/03/20 Goldman Sachs
Adaptive Biotechnologies initiated with a Buy at Goldman Sachs
05/19/20 Guggenheim
Adaptive Biotechnologies price target raised to $50 from $44 at Guggenheim
TBIO Translate Bio
$15.60 /

-0.14 (-0.89%)

07/07/20 H.C. Wainwright
Translate Bio price target raised to $32 from $18 at H.C. Wainwright
07/06/20
Fly Intel: Top five analyst initiations
07/06/20 William Blair
Translate Bio initiated with an Outperform at William Blair
06/26/20 Truist
Translate Bio initiated with a Buy at SunTrust
EBS Emergent BioSolutions
$122.01 /

+4.045 (+3.43%)

07/17/20 Cantor Fitzgerald
Emergent BioSolutions price target raised to $110 from $85 at Cantor Fitzgerald
07/02/20 Wells Fargo
Emergent BioSolutions price target raised to $93 from $85 at Wells Fargo
06/26/20 Raymond James
Vaxart already had vaccine deals with Emergent, Kindred, notes Raymond James
06/08/20 Guggenheim
Emergent BioSolutions price target lowered to $87 from $101 at Guggenheim
ITCI Intra-Cellular
$20.77 /

-0.15 (-0.72%)

06/04/20 Cantor Fitzgerald
Cantor reiterates $37 target on Intra-Cellular ahead of Phase 3 data
03/03/20 BTIG
Intra-Cellular price target lowered to $68 from $73 at BTIG
02/20/20
Fly Intel: Top five analyst initiations
02/19/20 Evercore ISI
Intra-Cellular initiated with an Outperform at Evercore ISI
KRTX Karuna Therapeutics
$86.82 /

-0.68 (-0.78%)

06/24/20 Oppenheimer
Karuna Therapeutics price target raised to $135 from $125 at Oppenheimer
06/02/20 Wedbush
Karuna Therapeutics price target raised to $126 from $117 at Wedbush
06/01/20 Goldman Sachs
Karuna price target raised to $131 from $115 at Goldman Sachs
05/31/20 Stifel
Karuna schizophrenia drug has blockbuster potential, says Stifel
ASMB Assembly Biosciences
$23.15 /

+0.03 (+0.13%)

07/21/20 Baird
Assembly Biosciences HBV deal a positive, says Baird
07/20/20 Piper Sandler
BeiGene inked smart deal with Assembly, says Piper Sandler
06/02/20 Mizuho
New clinical paper potentially supports Assembly stoppage criteria, says Mizuho
10/17/19 Baird
Assembly Biosciences abstract data encouraging, says Baird
NCNA NuCana
$6.55 /

+0.4 (+6.50%)

07/24/20
Fly Intel: Top five analyst initiations
07/24/20 Oppenheimer
NuCana initiated with an Outperform at Oppenheimer
07/23/20 Oppenheimer
NuCana initiated with an Outperform at Oppenheimer
01/27/20 William Blair
NuCana undervalued as first patients dosed in Phase 3 study, says William Blair
AXSM Axsome Therapeutics
$74.50 /

-1.82 (-2.38%)

07/13/20 Oppenheimer
Relmada Therapeutics initiated with an Outperform at Oppenheimer
04/28/20 Guggenheim
Axsome Therapeutics price target raised to $200 from $158 at Guggenheim
04/28/20 Truist
Axsome Therapeutics price target raised to $200 from $145 at SunTrust
04/28/20 Cantor Fitzgerald
Axsome Therapeutics price target raised to $131 from $125 at Cantor Fitzgerald
OVID Ovid Therapeutics
$6.61 /

-0.16 (-2.36%)

07/14/20 Citi
Ovid Therapeutics price target raised to $9 from $8 at Citi
06/18/20 Cantor Fitzgerald
Ovid Therapeutics price target raised to $13 from $7 at Cantor Fitzgerald
05/22/20 Cantor Fitzgerald
Zynerba price target raised to $21 from $12 at Cantor Fitzgerald
05/07/20 Piper Sandler
Ovid's gaboxadol data in Fragile X 'promising,' says Piper Sandler
ALLK Allakos
$78.92 /

-0.57 (-0.72%)

03/25/20 Jefferies
Allakos starts two pivotals on time despite skepticism, says Jefferies
03/12/20 SMBC Nikko
Allakos initiated with an Underperform at SMBC Nikko
02/27/20 Barclays
Allakos initiated with an Underweight at Barclays
02/27/20 Barclays
Allakos initiated with an Underweight at Barclays
NBIX Neurocrine
$124.09 /

+0.92 (+0.75%)

08/04/20 Canaccord
Neurocrine price target raised to $145 from $134 at Canaccord
08/04/20 SVB Leerink
Neurocrine price target raised to $120 from $105 at SVB Leerink
08/04/20 Piper Sandler
Neurocrine price target raised to $145 from $141 at Piper Sandler
08/04/20 H.C. Wainwright
Neurocrine price target raised to $140 from $131 at H.C. Wainwright
XENE Xenon Pharmaceuticals
$11.51 /

+ (+0.00%)

07/21/20
Fly Intel: Top five analyst initiations
07/21/20 Needham
Xenon Pharmaceuticals initiated with a Buy at Needham
07/20/20 Needham
Xenon Pharmaceuticals initiated with a Buy at Needham
06/01/20
Fly Intel: Top five analyst initiations
CRSP Crispr Therapeutics
$91.70 /

-0.85 (-0.92%)

07/28/20 Needham
Crispr Therapeutics price target raised to $105 from $84 at Needham
07/28/20 Wells Fargo
Crispr Therapeutics price target raised to $110 from $95 at Wells Fargo
07/28/20 Oppenheimer
Crispr Therapeutics price target raised to $105 from $89 at Oppenheimer
07/28/20 Barclays
Crispr Therapeutics price target raised to $102 from $65 at Barclays
BEAM Beam Therapeutics
$19.00 /

+0.03 (+0.16%)

03/02/20
Fly Intel: Top five analyst initiations
03/02/20 Wedbush
Wedbush bullish on Beam Therapeutics, initiates with an Outperform
03/02/20 JPMorgan
Beam Therapeutics initiated with an Overweight at JPMorgan
03/02/20 Wedbush
Beam Therapeutics initiated with an Outperform at Wedbush
GBT Global Blood Therapeutics
$68.59 /

-2.08 (-2.94%)

07/20/20 Roth Capital
Global Blood Therapeutics initiated with a Buy at Roth Capital
07/13/20 BofA
Global Blood Therapeutics initiated with a Buy at BofA
07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
06/12/20 Wells Fargo
Global Blood's Oxbryta efficacy bar 'tough to surpass,' says Wells Fargo
IONS Ionis Pharmaceuticals
$58.45 /

-0.78 (-1.32%)

07/20/20 BMO Capital
Alnylam price target raised to $196 from $173 at BMO Capital
06/05/20 Citi
Ionis Pharmaceuticals price target raised to $80 from $71 at Citi
05/12/20 RBC Capital
Ionis Pharmaceuticals initiated with an Outperform at RBC Capital
04/22/20 Jefferies
Jefferies remains cautious on Ionis after report from partner Biogen
RTRX Retrophin
$20.19 /

+ (+0.00%)

07/13/20 BMO Capital
Retrophin price target lowered to $31 from $34 at BMO Capital
06/16/20 BTIG
Retrophin initiated with a Buy at BTIG
02/25/20 Barclays
Retrophin downgraded to Equal Weight from Overweight at Barclays
01/13/20 JMP Securities
JMP says continues to like Retrophin opportunity
XENE Xenon Pharmaceuticals
$11.51 /

+ (+0.00%)

TBIO Translate Bio
$15.60 /

-0.14 (-0.89%)

RTRX Retrophin
$20.19 /

+ (+0.00%)

RGEN Repligen
$155.50 /

-3.02 (-1.91%)

RCUS Arcus Biosciences
$20.42 /

-0.61 (-2.90%)

PIRS Pieris Pharmaceuticals
$2.68 /

-0.025 (-0.92%)

OVID Ovid Therapeutics
$6.61 /

-0.16 (-2.36%)

NCNA NuCana
$6.55 /

+0.4 (+6.50%)

NBIX Neurocrine
$124.09 /

+0.92 (+0.75%)

KRTX Karuna Therapeutics
$86.82 /

-0.68 (-0.78%)

ITCI Intra-Cellular
$20.77 /

-0.15 (-0.72%)

IONS Ionis Pharmaceuticals
$58.45 /

-0.78 (-1.32%)

GRTS Gritstone Oncology
$3.35 /

+0.03 (+0.90%)

GBT Global Blood Therapeutics
$68.59 /

-2.08 (-2.94%)

FATE Fate Therapeutics
$32.33 /

-0.92 (-2.77%)

EXEL Exelixis
$23.06 /

-0.64 (-2.70%)

EBS Emergent BioSolutions
$122.01 /

+4.045 (+3.43%)

CRSP Crispr Therapeutics
$91.70 /

-0.85 (-0.92%)

CLLS Cellectis
$17.44 /

+ (+0.00%)

CALA Calithera Biosciences
$4.85 /

-0.02 (-0.41%)

BEAM Beam Therapeutics
$19.00 /

+0.03 (+0.16%)

AXSM Axsome Therapeutics
$74.50 /

-1.82 (-2.38%)

AUTL Autolus Therapeutics
$13.92 /

+ (+0.00%)

ASMB Assembly Biosciences
$23.15 /

+0.03 (+0.13%)

ALLK Allakos
$78.92 /

-0.57 (-0.72%)

AGEN Agenus
$3.20 /

-0.055 (-1.69%)

ADPT Adaptive Biotechnologies
$39.49 /

+0.12 (+0.30%)

  • 16
    Jul
  • 01
    Jul
  • 26
    Jun
  • 09
    Jun
  • 09
    Jun
  • 29
    May
  • 13
    May
  • 16
    Apr
  • 06
    Feb
  • 23
    Jan
  • 23
    Jan
  • 22
    Jan
  • 24
    Jan
  • 08
    Jan
  • 19
    Dec
  • 12
    Dec
  • 21
    Nov
  • 21
    Nov
  • 04
    Oct
  • 18
    Sep
  • 12
    Sep
  • 12
    Sep
  • 07
    Aug
RCUS Arcus Biosciences
$20.42 /

-0.61 (-2.90%)

ALLK Allakos
$78.92 /

-0.57 (-0.72%)

TBIO Translate Bio
$15.60 /

-0.14 (-0.89%)

RCUS Arcus Biosciences
$20.42 /

-0.61 (-2.90%)

PIRS Pieris Pharmaceuticals
$2.68 /

-0.025 (-0.92%)

OVID Ovid Therapeutics
$6.61 /

-0.16 (-2.36%)

NCNA NuCana
$6.55 /

+0.4 (+6.50%)

NBIX Neurocrine
$124.09 /

+0.92 (+0.75%)

GBT Global Blood Therapeutics
$68.59 /

-2.08 (-2.94%)

FATE Fate Therapeutics
$32.33 /

-0.92 (-2.77%)

EXEL Exelixis
$23.06 /

-0.64 (-2.70%)

EBS Emergent BioSolutions
$122.01 /

+4.045 (+3.43%)

CRSP Crispr Therapeutics
$91.70 /

-0.85 (-0.92%)

CLLS Cellectis
$17.44 /

+ (+0.00%)

CALA Calithera Biosciences
$4.85 /

-0.02 (-0.41%)

BEAM Beam Therapeutics
$19.00 /

+0.03 (+0.16%)

AXSM Axsome Therapeutics
$74.50 /

-1.82 (-2.38%)

ALLK Allakos
$78.92 /

-0.57 (-0.72%)

ADPT Adaptive Biotechnologies
$39.49 /

+0.12 (+0.30%)

RCUS Arcus Biosciences
$20.42 /

-0.61 (-2.90%)

OVID Ovid Therapeutics
$6.61 /

-0.16 (-2.36%)

ITCI Intra-Cellular
$20.77 /

-0.15 (-0.72%)

IONS Ionis Pharmaceuticals
$58.45 /

-0.78 (-1.32%)

EXEL Exelixis
$23.06 /

-0.64 (-2.70%)

AXSM Axsome Therapeutics
$74.50 /

-1.82 (-2.38%)

Conference/Events
William Blair to hold a virtual conference » 08:49
08/04/20
08/04
08:49
08/04/20
08:49
RCUS

Arcus Biosciences

$21.03 /

+1.34 (+6.81%)

, AGEN

Agenus

$3.25 /

+0.205 (+6.73%)

, EXEL

Exelixis

$23.70 /

+0.64 (+2.78%)

, CALA

Calithera Biosciences

$4.87 /

+0.15 (+3.18%)

, RGEN

Repligen

$158.52 /

+7.46 (+4.94%)

, PIRS

Pieris Pharmaceuticals

$2.71 /

+0.135 (+5.25%)

, CYAD

Celyad

$9.87 /

+ (+0.00%)

, FATE

Fate Therapeutics

$33.25 /

+2 (+6.40%)

, CLLS

Cellectis

$17.44 /

+1.77 (+11.30%)

, AUTL

Autolus Therapeutics

$13.92 /

+0.72 (+5.45%)

, GRTS

Gritstone Oncology

$3.32 /

+0.115 (+3.59%)

, ADPT

Adaptive Biotechnologies

$39.37 /

+1.99 (+5.32%)

, TBIO

Translate Bio

$15.74 /

+0.56 (+3.69%)

, EBS

Emergent BioSolutions

$117.97 /

+6.755 (+6.07%)

, ITCI

Intra-Cellular

$20.92 /

+1.11 (+5.60%)

, KRTX

Karuna Therapeutics

$87.50 /

+5.89 (+7.22%)

, ASMB

Assembly Biosciences

$23.12 /

+0.9 (+4.05%)

, NCNA

NuCana

$6.15 /

+0.65 (+11.82%)

, AXSM

Axsome Therapeutics

$76.32 /

+4.97 (+6.97%)

, OVID

Ovid Therapeutics

$6.77 /

+0.32 (+4.96%)

, ALLK

Allakos

$79.49 /

+4.36 (+5.80%)

, NBIX

Neurocrine

$123.17 /

+2.8 (+2.33%)

, XENE

Xenon Pharmaceuticals

$11.51 /

+0.55 (+5.02%)

, CRSP

Crispr Therapeutics

$92.55 /

+7.15 (+8.37%)

, BEAM

Beam Therapeutics

$18.97 /

-0.31 (-1.61%)

, GBT

Global Blood Therapeutics

$70.67 /

+3.24 (+4.80%)

, IONS

Ionis Pharmaceuticals

$59.23 /

+1.7 (+2.95%)

, RTRX

Retrophin

$20.19 /

+0.385 (+1.94%)

Biotech Focus Virtual…

Biotech Focus Virtual Conference 2020 will be held on August 4-6 beginning at 10 am on August 4. Webcast Link

ShowHide Related Items >><<
XENE Xenon Pharmaceuticals
$11.51 /

+0.55 (+5.02%)

TBIO Translate Bio
$15.74 /

+0.56 (+3.69%)

RTRX Retrophin
$20.19 /

+0.385 (+1.94%)

RGEN Repligen
$158.52 /

+7.46 (+4.94%)

RCUS Arcus Biosciences
$21.03 /

+1.34 (+6.81%)

PIRS Pieris Pharmaceuticals
$2.71 /

+0.135 (+5.25%)

OVID Ovid Therapeutics
$6.77 /

+0.32 (+4.96%)

NCNA NuCana
$6.15 /

+0.65 (+11.82%)

NBIX Neurocrine
$123.17 /

+2.8 (+2.33%)

KRTX Karuna Therapeutics
$87.50 /

+5.89 (+7.22%)

ITCI Intra-Cellular
$20.92 /

+1.11 (+5.60%)

IONS Ionis Pharmaceuticals
$59.23 /

+1.7 (+2.95%)

GRTS Gritstone Oncology
$3.32 /

+0.115 (+3.59%)

GBT Global Blood Therapeutics
$70.67 /

+3.24 (+4.80%)

FATE Fate Therapeutics
$33.25 /

+2 (+6.40%)

EXEL Exelixis
$23.70 /

+0.64 (+2.78%)

EBS Emergent BioSolutions
$117.97 /

+6.755 (+6.07%)

CYAD Celyad
$9.87 /

+ (+0.00%)

CRSP Crispr Therapeutics
$92.55 /

+7.15 (+8.37%)

CLLS Cellectis
$17.44 /

+1.77 (+11.30%)

CALA Calithera Biosciences
$4.87 /

+0.15 (+3.18%)

BEAM Beam Therapeutics
$18.97 /

-0.31 (-1.61%)

AXSM Axsome Therapeutics
$76.32 /

+4.97 (+6.97%)

AUTL Autolus Therapeutics
$13.92 /

+0.72 (+5.45%)

ASMB Assembly Biosciences
$23.12 /

+0.9 (+4.05%)

ALLK Allakos
$79.49 /

+4.36 (+5.80%)

AGEN Agenus
$3.25 /

+0.205 (+6.73%)

ADPT Adaptive Biotechnologies
$39.37 /

+1.99 (+5.32%)

RCUS Arcus Biosciences
$21.03 /

+1.34 (+6.81%)

06/10/20 Truist
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/03/20 SVB Leerink
Gilead upgraded to Outperform at SVB Leerink on remdesivir sales, Arcus deal
06/02/20 Citi
Arcus Biosciences price target raised to $41 from $15 at Citi
05/27/20 Raymond James
Raymond James keeps Market Perform on Gilead following Arcus partnership
AGEN Agenus
$3.25 /

+0.205 (+6.73%)

01/09/20 B. Riley Securities
Arbutus Biopharma price target raised to $6 from $3 at B. Riley FBR
11/19/19
Fly Intel: Top five analyst initiations
11/19/19 B. Riley Securities
Agenus resumed with a Buy at B. Riley FBR
11/19/19 B. Riley Securities
Agenus resumed with a Buy at B. Riley FBR
EXEL Exelixis
$23.70 /

+0.64 (+2.78%)

06/30/20 Piper Sandler
Exelixis' 2/3 Phase III Contact studies underway, says Piper Sandler
05/14/20 Truist
Exelixis price target raised to $40 from $35 at SunTrust
05/13/20 Piper Sandler
Exelixis mCRPC data for CABOMETYX may accelerate approval, says Piper Sandler
05/06/20 Piper Sandler
Exelixis price target raised to $30 from $23 at Piper Sandler
CALA Calithera Biosciences
$4.87 /

+0.15 (+3.18%)

05/11/20 Citi
Calithera Biosciences price target raised to $10 from $7 at Citi
05/08/20 H.C. Wainwright
Calithera Biosciences price target raised to $9.50 from $7 at H.C. Wainwright
03/27/20
Fly Intel: Top five analyst initiations
03/27/20 Jefferies
Jefferies starts Calithera at Buy ahead of three data catalysts
RGEN Repligen
$158.52 /

+7.46 (+4.94%)

06/30/20 H.C. Wainwright
Repligen price target raised to $151 from $143 at H.C. Wainwright
05/27/20 Stifel
Repligen price target raised to $150 from $135 at Stifel
05/07/20 Craig-Hallum
Repligen price target raised to $145 from $120 at Craig-Hallum
05/07/20 H.C. Wainwright
Repligen price target raised to $143 from $100 at H.C. Wainwright
PIRS Pieris Pharmaceuticals
$2.71 /

+0.135 (+5.25%)

03/13/20 Baird
Baird upgrades Pieris Pharmaceuticals as pipeline updates expected
03/13/20 Baird
Pieris Pharmaceuticals upgraded to Outperform from Neutral at Baird
03/12/20 H.C. Wainwright
Increased visibility in 2020 expected for Pieris, says H.C. Wainwright
01/27/20 H.C. Wainwright
Pieris Pharmaceuticals price target raised to $9 from $7 at H.C. Wainwright
CYAD Celyad
$9.87 /

+ (+0.00%)

03/26/20 Wells Fargo
Celyad price target lowered to $20 from $44 at Wells Fargo
03/25/20 H.C. Wainwright
Celyad price target lowered to $37 from $43 at H.C. Wainwright
FATE Fate Therapeutics
$33.25 /

+2 (+6.40%)

06/10/20 Oppenheimer
Fate Therapeutics price target raised to $40 from $34 at Oppenheimer
06/09/20 Piper Sandler
Fate Therapeutics price target lowered to $59 from $63 at Piper Sandler
05/13/20
Fly Intel: Top five analyst initiations
05/13/20 H.C. Wainwright
Fate Therapeutics initiated with a Buy at H.C. Wainwright
CLLS Cellectis
$17.44 /

+1.77 (+11.30%)

05/12/20
Fly Intel: Top five analyst initiations
05/11/20 Baird
Cellectis initiated with an Outperform at Baird
03/06/20 Citi
Cellectis price target raised to $16 from $14 at Citi
03/06/20 Goldman Sachs
Cellectis downgraded to Sell from Neutral at Goldman Sachs
AUTL Autolus Therapeutics
$13.92 /

+0.72 (+5.45%)

07/31/20
Fly Intel: Top five analyst initiations
07/31/20 JPMorgan
Autolus Therapeutics initiated with an Overweight at JPMorgan
07/22/20 Truist
Autolus Therapeutics initiated with a Buy at SunTrust
07/22/20 Truist
Autolus Therapeutics initiated with a Buy at SunTrust
GRTS Gritstone Oncology
$3.32 /

+0.115 (+3.59%)

07/14/20 BTIG
Gritstone Oncology price target lowered to $17 from $31 at BTIG
ADPT Adaptive Biotechnologies
$39.37 /

+1.99 (+5.32%)

06/18/20 Guggenheim
Adaptive to benefit from increased MRD testing by oncologists, says Guggenheim
06/03/20
Fly Intel: Top five analyst initiations
06/03/20 Goldman Sachs
Adaptive Biotechnologies initiated with a Buy at Goldman Sachs
05/19/20 Guggenheim
Adaptive Biotechnologies price target raised to $50 from $44 at Guggenheim
TBIO Translate Bio
$15.74 /

+0.56 (+3.69%)

07/07/20 H.C. Wainwright
Translate Bio price target raised to $32 from $18 at H.C. Wainwright
07/06/20
Fly Intel: Top five analyst initiations
07/06/20 William Blair
Translate Bio initiated with an Outperform at William Blair
06/26/20 Truist
Translate Bio initiated with a Buy at SunTrust
EBS Emergent BioSolutions
$117.97 /

+6.755 (+6.07%)

07/17/20 Cantor Fitzgerald
Emergent BioSolutions price target raised to $110 from $85 at Cantor Fitzgerald
07/02/20 Wells Fargo
Emergent BioSolutions price target raised to $93 from $85 at Wells Fargo
06/26/20 Raymond James
Vaxart already had vaccine deals with Emergent, Kindred, notes Raymond James
06/08/20 Guggenheim
Emergent BioSolutions price target lowered to $87 from $101 at Guggenheim
ITCI Intra-Cellular
$20.92 /

+1.11 (+5.60%)

06/04/20 Cantor Fitzgerald
Cantor reiterates $37 target on Intra-Cellular ahead of Phase 3 data
03/03/20 BTIG
Intra-Cellular price target lowered to $68 from $73 at BTIG
02/20/20
Fly Intel: Top five analyst initiations
02/19/20 Evercore ISI
Intra-Cellular initiated with an Outperform at Evercore ISI
KRTX Karuna Therapeutics
$87.50 /

+5.89 (+7.22%)

06/24/20 Oppenheimer
Karuna Therapeutics price target raised to $135 from $125 at Oppenheimer
06/02/20 Wedbush
Karuna Therapeutics price target raised to $126 from $117 at Wedbush
06/01/20 Goldman Sachs
Karuna price target raised to $131 from $115 at Goldman Sachs
05/31/20 Stifel
Karuna schizophrenia drug has blockbuster potential, says Stifel
ASMB Assembly Biosciences
$23.12 /

+0.9 (+4.05%)

07/21/20 Baird
Assembly Biosciences HBV deal a positive, says Baird
07/20/20 Piper Sandler
BeiGene inked smart deal with Assembly, says Piper Sandler
06/02/20 Mizuho
New clinical paper potentially supports Assembly stoppage criteria, says Mizuho
10/17/19 Baird
Assembly Biosciences abstract data encouraging, says Baird
NCNA NuCana
$6.15 /

+0.65 (+11.82%)

07/24/20
Fly Intel: Top five analyst initiations
07/24/20 Oppenheimer
NuCana initiated with an Outperform at Oppenheimer
07/23/20 Oppenheimer
NuCana initiated with an Outperform at Oppenheimer
01/27/20 William Blair
NuCana undervalued as first patients dosed in Phase 3 study, says William Blair
AXSM Axsome Therapeutics
$76.32 /

+4.97 (+6.97%)

07/13/20 Oppenheimer
Relmada Therapeutics initiated with an Outperform at Oppenheimer
04/28/20 Guggenheim
Axsome Therapeutics price target raised to $200 from $158 at Guggenheim
04/28/20 Truist
Axsome Therapeutics price target raised to $200 from $145 at SunTrust
04/28/20 Cantor Fitzgerald
Axsome Therapeutics price target raised to $131 from $125 at Cantor Fitzgerald
OVID Ovid Therapeutics
$6.77 /

+0.32 (+4.96%)

07/14/20 Citi
Ovid Therapeutics price target raised to $9 from $8 at Citi
06/18/20 Cantor Fitzgerald
Ovid Therapeutics price target raised to $13 from $7 at Cantor Fitzgerald
05/22/20 Cantor Fitzgerald
Zynerba price target raised to $21 from $12 at Cantor Fitzgerald
05/07/20 Piper Sandler
Ovid's gaboxadol data in Fragile X 'promising,' says Piper Sandler
ALLK Allakos
$79.49 /

+4.36 (+5.80%)

03/25/20 Jefferies
Allakos starts two pivotals on time despite skepticism, says Jefferies
03/12/20 SMBC Nikko
Allakos initiated with an Underperform at SMBC Nikko
02/27/20 Barclays
Allakos initiated with an Underweight at Barclays
02/27/20 Barclays
Allakos initiated with an Underweight at Barclays
NBIX Neurocrine
$123.17 /

+2.8 (+2.33%)

08/04/20 Canaccord
Neurocrine price target raised to $145 from $134 at Canaccord
08/04/20 SVB Leerink
Neurocrine price target raised to $120 from $105 at SVB Leerink
08/04/20 Piper Sandler
Neurocrine price target raised to $145 from $141 at Piper Sandler
08/04/20 H.C. Wainwright
Neurocrine price target raised to $140 from $131 at H.C. Wainwright
XENE Xenon Pharmaceuticals
$11.51 /

+0.55 (+5.02%)

07/21/20
Fly Intel: Top five analyst initiations
07/21/20 Needham
Xenon Pharmaceuticals initiated with a Buy at Needham
07/20/20 Needham
Xenon Pharmaceuticals initiated with a Buy at Needham
06/01/20
Fly Intel: Top five analyst initiations
CRSP Crispr Therapeutics
$92.55 /

+7.15 (+8.37%)

07/28/20 Needham
Crispr Therapeutics price target raised to $105 from $84 at Needham
07/28/20 Wells Fargo
Crispr Therapeutics price target raised to $110 from $95 at Wells Fargo
07/28/20 Oppenheimer
Crispr Therapeutics price target raised to $105 from $89 at Oppenheimer
07/28/20 Barclays
Crispr Therapeutics price target raised to $102 from $65 at Barclays
BEAM Beam Therapeutics
$18.97 /

-0.31 (-1.61%)

03/02/20
Fly Intel: Top five analyst initiations
03/02/20 Wedbush
Wedbush bullish on Beam Therapeutics, initiates with an Outperform
03/02/20 JPMorgan
Beam Therapeutics initiated with an Overweight at JPMorgan
03/02/20 Wedbush
Beam Therapeutics initiated with an Outperform at Wedbush
GBT Global Blood Therapeutics
$70.67 /

+3.24 (+4.80%)

07/20/20 Roth Capital
Global Blood Therapeutics initiated with a Buy at Roth Capital
07/13/20 BofA
Global Blood Therapeutics initiated with a Buy at BofA
07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
06/12/20 Wells Fargo
Global Blood's Oxbryta efficacy bar 'tough to surpass,' says Wells Fargo
IONS Ionis Pharmaceuticals
$59.23 /

+1.7 (+2.95%)

07/20/20 BMO Capital
Alnylam price target raised to $196 from $173 at BMO Capital
06/05/20 Citi
Ionis Pharmaceuticals price target raised to $80 from $71 at Citi
05/12/20 RBC Capital
Ionis Pharmaceuticals initiated with an Outperform at RBC Capital
04/22/20 Jefferies
Jefferies remains cautious on Ionis after report from partner Biogen
RTRX Retrophin
$20.19 /

+0.385 (+1.94%)

07/13/20 BMO Capital
Retrophin price target lowered to $31 from $34 at BMO Capital
06/16/20 BTIG
Retrophin initiated with a Buy at BTIG
02/25/20 Barclays
Retrophin downgraded to Equal Weight from Overweight at Barclays
01/13/20 JMP Securities
JMP says continues to like Retrophin opportunity
XENE Xenon Pharmaceuticals
$11.51 /

+0.55 (+5.02%)

TBIO Translate Bio
$15.74 /

+0.56 (+3.69%)

RTRX Retrophin
$20.19 /

+0.385 (+1.94%)

RGEN Repligen
$158.52 /

+7.46 (+4.94%)

RCUS Arcus Biosciences
$21.03 /

+1.34 (+6.81%)

PIRS Pieris Pharmaceuticals
$2.71 /

+0.135 (+5.25%)

OVID Ovid Therapeutics
$6.77 /

+0.32 (+4.96%)

NCNA NuCana
$6.15 /

+0.65 (+11.82%)

NBIX Neurocrine
$123.17 /

+2.8 (+2.33%)

KRTX Karuna Therapeutics
$87.50 /

+5.89 (+7.22%)

ITCI Intra-Cellular
$20.92 /

+1.11 (+5.60%)

IONS Ionis Pharmaceuticals
$59.23 /

+1.7 (+2.95%)

GRTS Gritstone Oncology
$3.32 /

+0.115 (+3.59%)

GBT Global Blood Therapeutics
$70.67 /

+3.24 (+4.80%)

FATE Fate Therapeutics
$33.25 /

+2 (+6.40%)

EXEL Exelixis
$23.70 /

+0.64 (+2.78%)

EBS Emergent BioSolutions
$117.97 /

+6.755 (+6.07%)

CRSP Crispr Therapeutics
$92.55 /

+7.15 (+8.37%)

CLLS Cellectis
$17.44 /

+1.77 (+11.30%)

CALA Calithera Biosciences
$4.87 /

+0.15 (+3.18%)

BEAM Beam Therapeutics
$18.97 /

-0.31 (-1.61%)

AXSM Axsome Therapeutics
$76.32 /

+4.97 (+6.97%)

AUTL Autolus Therapeutics
$13.92 /

+0.72 (+5.45%)

ASMB Assembly Biosciences
$23.12 /

+0.9 (+4.05%)

ALLK Allakos
$79.49 /

+4.36 (+5.80%)

AGEN Agenus
$3.25 /

+0.205 (+6.73%)

ADPT Adaptive Biotechnologies
$39.37 /

+1.99 (+5.32%)

  • 16
    Jul
  • 01
    Jul
  • 26
    Jun
  • 09
    Jun
  • 09
    Jun
  • 29
    May
  • 13
    May
  • 16
    Apr
  • 06
    Feb
  • 23
    Jan
  • 23
    Jan
  • 22
    Jan
  • 24
    Jan
  • 08
    Jan
  • 19
    Dec
  • 12
    Dec
  • 21
    Nov
  • 21
    Nov
  • 04
    Oct
  • 18
    Sep
  • 12
    Sep
  • 12
    Sep
  • 07
    Aug
RCUS Arcus Biosciences
$21.03 /

+1.34 (+6.81%)

ALLK Allakos
$79.49 /

+4.36 (+5.80%)

TBIO Translate Bio
$15.74 /

+0.56 (+3.69%)

RCUS Arcus Biosciences
$21.03 /

+1.34 (+6.81%)

PIRS Pieris Pharmaceuticals
$2.71 /

+0.135 (+5.25%)

OVID Ovid Therapeutics
$6.77 /

+0.32 (+4.96%)

NCNA NuCana
$6.15 /

+0.65 (+11.82%)

NBIX Neurocrine
$123.17 /

+2.8 (+2.33%)

GBT Global Blood Therapeutics
$70.67 /

+3.24 (+4.80%)

FATE Fate Therapeutics
$33.25 /

+2 (+6.40%)

EXEL Exelixis
$23.70 /

+0.64 (+2.78%)

EBS Emergent BioSolutions
$117.97 /

+6.755 (+6.07%)

CRSP Crispr Therapeutics
$92.55 /

+7.15 (+8.37%)

CLLS Cellectis
$17.44 /

+1.77 (+11.30%)

CALA Calithera Biosciences
$4.87 /

+0.15 (+3.18%)

BEAM Beam Therapeutics
$18.97 /

-0.31 (-1.61%)

AXSM Axsome Therapeutics
$76.32 /

+4.97 (+6.97%)

ALLK Allakos
$79.49 /

+4.36 (+5.80%)

ADPT Adaptive Biotechnologies
$39.37 /

+1.99 (+5.32%)

RCUS Arcus Biosciences
$21.03 /

+1.34 (+6.81%)

OVID Ovid Therapeutics
$6.77 /

+0.32 (+4.96%)

ITCI Intra-Cellular
$20.92 /

+1.11 (+5.60%)

IONS Ionis Pharmaceuticals
$59.23 /

+1.7 (+2.95%)

EXEL Exelixis
$23.70 /

+0.64 (+2.78%)

AXSM Axsome Therapeutics
$76.32 /

+4.97 (+6.97%)

On The Fly
Fly Intel: After-Hours Movers » 19:08
07/06/20
07/06
19:08
07/06/20
19:08
OTIC

Otonomy

$3.19 /

+0.02 (+0.63%)

, XSPA

XpresSpa

$3.79 /

-0.2 (-5.01%)

, CEMI

Chembio Diagnostics

$4.02 /

-0.15 (-3.60%)

, GLDD

Great Lakes Dredge

$8.85 /

+0.04 (+0.45%)

, PSN

Parsons

$34.56 /

-0.37 (-1.06%)

, KINS

Kingstone Companies

$4.41 /

-0.01 (-0.23%)

, MARK

Remark Holdings

$2.61 /

+0.235 (+9.89%)

, CLLS

Cellectis

$19.04 /

+0.42 (+2.26%)

, TRIB

Trinity Biotech

$2.54 /

+0.23 (+9.96%)

, RVMD

Revolution Medicines

$29.27 /

-1.73 (-5.58%)

, PCRX

Pacira

$54.13 /

+1.93 (+3.70%)

, ARE

Alexandria Real Estate

$164.78 /

-0.08 (-0.05%)

, KMI

Kinder Morgan

$15.20 /

+0.07 (+0.46%)

Check out this evening's…

ShowHide Related Items >><<
XSPA XpresSpa
$3.79 /

-0.2 (-5.01%)

TRIB Trinity Biotech
$2.54 /

+0.23 (+9.96%)

RVMD Revolution Medicines
$29.27 /

-1.73 (-5.58%)

PSN Parsons
$34.56 /

-0.37 (-1.06%)

PCRX Pacira
$54.13 /

+1.93 (+3.70%)

OTIC Otonomy
$3.19 /

+0.02 (+0.63%)

MARK Remark Holdings
$2.61 /

+0.235 (+9.89%)

KMI Kinder Morgan
$15.20 /

+0.07 (+0.46%)

GLDD Great Lakes Dredge
$8.85 /

+0.04 (+0.45%)

CLLS Cellectis
$19.04 /

+0.42 (+2.26%)

CEMI Chembio Diagnostics
$4.02 /

-0.15 (-3.60%)

ARE Alexandria Real Estate
$164.78 /

-0.08 (-0.05%)

OTIC Otonomy
$3.19 /

+0.02 (+0.63%)

06/15/20 Piper Sandler
Piper remains optimistic on Otonomy ahead of near-term clinical readouts
06/01/20 Oppenheimer
Otonomy assumed with an Outperform at Oppenheimer
05/07/20 Piper Sandler
Piper still believes in potential success of three key Otonomy programs
02/07/20 Piper Sandler
Otonomy should be bought ahead of near-term readouts, says Piper Sandler
XSPA XpresSpa
$3.79 /

-0.2 (-5.01%)

CEMI Chembio Diagnostics
$4.02 /

-0.15 (-3.60%)

06/17/20
Fly Intel: Top five analyst downgrades
06/17/20 Craig-Hallum
Chembio Diagnostics downgraded to Hold from Buy at Craig-Hallum
06/17/20 Colliers
Chembio Diagnostics downgraded to Neutral from Buy at Colliers
06/17/20 Canaccord
Chembio Diagnostics downgraded to Hold at Canaccord
GLDD Great Lakes Dredge
$8.85 /

+0.04 (+0.45%)

PSN Parsons
$34.56 /

-0.37 (-1.06%)

05/05/20 Wells Fargo
Parsons price target raised to $39 from $33 at Wells Fargo
04/15/20 Benchmark
Parsons initiated with a Buy at Benchmark
04/02/20 Wells Fargo
Parsons price target lowered to $33 from $42 at Wells Fargo
03/30/20 William Blair
Parsons initiated with an Outperform at William Blair
KINS Kingstone Companies
$4.41 /

-0.01 (-0.23%)

MARK Remark Holdings
$2.61 /

+0.235 (+9.89%)

06/10/20 Roth Capital
Roth checks point to Kent Services as Remark Holdings distribution partner
05/27/20 Roth Capital
Wynn video 'clearly shows' Remark AI technology in use, says Roth Capital
07/15/19 Roth Capital
Sharecare liquidity event would help capitalize Remark AI business, says Roth Capital
CLLS Cellectis
$19.04 /

+0.42 (+2.26%)

05/12/20
Fly Intel: Top five analyst initiations
05/11/20 Baird
Cellectis initiated with an Outperform at Baird
03/06/20 Citi
Cellectis price target raised to $16 from $14 at Citi
03/06/20 Goldman Sachs
Cellectis downgraded to Sell from Neutral at Goldman Sachs
TRIB Trinity Biotech
$2.54 /

+0.23 (+9.96%)

RVMD Revolution Medicines
$29.27 /

-1.73 (-5.58%)

05/21/20
Fly Intel: Top five analyst initiations
05/21/20 H.C. Wainwright
Revolution Medicines initiated with a Buy at H.C. Wainwright
03/09/20
Fly Intel: Top five analyst initiations
03/09/20 Cowen
Revolution Medicines initiated with an Outperform at Cowen
PCRX Pacira
$54.13 /

+1.93 (+3.70%)

07/06/20 Needham
Pacira price target raised to $64 from $52 at Needham
07/06/20 Piper Sandler
Pacira price target raised to $65 from $49 at Piper Sandler
07/01/20 RBC Capital
Pacira price target raised to $62 from $56 at RBC Capital
06/30/20 SVB Leerink
Pacira price target raised to $58 from $45 at SVB Leerink
ARE Alexandria Real Estate
$164.78 /

-0.08 (-0.05%)

06/08/20 JMP Securities
Alexandria Real Estate resumed with an Outperform at JMP Securities
02/04/20 Mizuho
Alexandria Real Estate assumed with a Buy at Mizuho
12/18/19 JPMorgan
JPMorgan makes 17 REIT rating changes in conjunction with 2020 outlook
12/18/19 RBC Capital
Alexandria Real Estate downgraded to Outperform from Top Pick at RBC Capital
KMI Kinder Morgan
$15.20 /

+0.07 (+0.46%)

07/06/20 Goldman Sachs
Kinder Morgan downgraded to Sell from Neutral at Goldman Sachs
05/18/20 BofA
Plains All American, GP Holdings cut to Underperform at BofA
04/07/20 Mizuho
Kinder Morgan price target lowered to $20 from $23 at Mizuho
03/24/20 Barclays
Kinder Morgan upgraded to Overweight from Equal Weight at Barclays
TRIB Trinity Biotech
$2.54 /

+0.23 (+9.96%)

PSN Parsons
$34.56 /

-0.37 (-1.06%)

PCRX Pacira
$54.13 /

+1.93 (+3.70%)

OTIC Otonomy
$3.19 /

+0.02 (+0.63%)

MARK Remark Holdings
$2.61 /

+0.235 (+9.89%)

KMI Kinder Morgan
$15.20 /

+0.07 (+0.46%)

KINS Kingstone Companies
$4.41 /

-0.01 (-0.23%)

GLDD Great Lakes Dredge
$8.85 /

+0.04 (+0.45%)

CLLS Cellectis
$19.04 /

+0.42 (+2.26%)

CEMI Chembio Diagnostics
$4.02 /

-0.15 (-3.60%)

ARE Alexandria Real Estate
$164.78 /

-0.08 (-0.05%)

  • 07
    Jul
  • 09
    Jul
  • 07
    May
  • 13
    Feb
  • 07
    Jan
KMI Kinder Morgan
$15.20 /

+0.07 (+0.46%)

ARE Alexandria Real Estate
$164.78 /

-0.08 (-0.05%)

RVMD Revolution Medicines
$29.27 /

-1.73 (-5.58%)

PSN Parsons
$34.56 /

-0.37 (-1.06%)

PCRX Pacira
$54.13 /

+1.93 (+3.70%)

MARK Remark Holdings
$2.61 /

+0.235 (+9.89%)

KMI Kinder Morgan
$15.20 /

+0.07 (+0.46%)

CEMI Chembio Diagnostics
$4.02 /

-0.15 (-3.60%)

XSPA XpresSpa
$3.79 /

-0.2 (-5.01%)

MARK Remark Holdings
$2.61 /

+0.235 (+9.89%)

KMI Kinder Morgan
$15.20 /

+0.07 (+0.46%)

CEMI Chembio Diagnostics
$4.02 /

-0.15 (-3.60%)

Hot Stocks
Cellectis says FDA places clinical hold on MELANI-01 study » 16:33
07/06/20
07/06
16:33
07/06/20
16:33
CLLS

Cellectis

$18.94 /

+0.32 (+1.72%)

Cellectis announced that…

Cellectis announced that the MELANI-01 trial has been placed on clinical hold by the U.S. Food and Drug Administration. This clinical hold which impacts one of the three Cellectis product candidates currently in clinical studies, was initiated following the submission of a safety report regarding one patient enrolled in the MELANI-01 study at dose level two (DL2), with relapsed and refractory multiple myeloma. This patient, who had been treated unsuccessfully, prior to enrollment with numerous lines of prior therapy, including autologous CAR T-cells, experienced a fatal treatment-emergent adverse event of cardiac arrest. Clinical evaluation of the case remains ongoing and additional details as to the immediate and underlying causes of this event are being collected. Of note, prior to the clinical hold being issued by the FDA, Cellectis had decided to expand enrollment at DL1, which may be the appropriate dose for further evaluation in the expansion portion of the trial and potentially the recommended Phase 2 dose based on an assessment of the preliminary clinical and translational data. The Company had begun executing updates to the clinical protocol to reflect this as well as to monitor and mitigate for additional potential risks given its novel mechanism of action. "We share the FDA's commitment to patient safety and are working collaboratively with the agency and the investigators to resolve this clinical hold," said Carrie Brownstein, MD, Chief Medical Officer, Cellectis. "The safety of patients enrolled in our clinical trials is our utmost priority and we at Cellectis remain committed to safely resuming the clinical development of UCART product candidate targeting CS1 for patients with multiple myeloma and unmet medical need."

ShowHide Related Items >><<
CLLS Cellectis
$18.94 /

+0.32 (+1.72%)

CLLS Cellectis
$18.94 /

+0.32 (+1.72%)

05/12/20
Fly Intel: Top five analyst initiations
05/11/20 Baird
Cellectis initiated with an Outperform at Baird
03/06/20 Citi
Cellectis price target raised to $16 from $14 at Citi
03/06/20 Goldman Sachs
Cellectis downgraded to Sell from Neutral at Goldman Sachs
CLLS Cellectis
$18.94 /

+0.32 (+1.72%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.